13
Mar
2023
Tag: Alzheimer’s Disease
21
Feb
2023
Bionest
Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis
What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
27
Jul
2021
Bionest
An Alzheimer’s Disease Milestone, But Questions Remain
Aduhelm, the first new treatment for Alzheimer’s disease in nearly 20 years, may be a long-awaited milestone for AD patients and caregivers but its reception has been mixed.
8
Apr
2019
Bionest
Alzheimer’s Disease Update
Scientific evidence increasingly points to brain inflammation as a major driver of Alzheimer’s disease (AD). Researchers have discovered that amyloid, one of the hallmarks of the disease, is antimicrobial and may help the immune system fight invaders to the brain. They theorize that accumulating amyloid plaques and tau tangles in response to infection set the...
24
Dec
2018
Bionest
New Approaches to an Earlier Alzheimer’s Disease Diagnosis
We have written previously about the need for earlier diagnosis for Alzheimer’s disease (AD) and other dementias, a capability that could both aid in the discovery and the development of new therapies, and increase the chances for better patient outcomes in slowing or preventing cognitive decline. Recently, researchers have presented data on several new non-invasive...
13
Aug
2018
Bionest
Positive Results Reported in Alzheimer’s Disease — But Questions Remain
In early July, Biogen and Eisai announced that analysis of their 18-month Phase 2 trial of BAN2401 revealed encouraging results, showing an effect on both lowering of amyloid levels and slowing of cognitive decline in patients treated with the highest dose of the drug. This spurred some analysts to hail the news as encouraging support...
24
May
2018
Bionest
Hot Topics in Neurology at AAN
We have been thinking for some time about the importance of biomarkers in both drug discovery and clinical medicine as they relate to Alzheimer’s (and our In Vivo publication also addresses this topic in depth). At the recent American Academy of Neurology (AAN) conference, there was also widespread interest in this topic, spurred in part...
10
May
2018
Bionest
BIO2018, here we come: Real-time oncology and biomarkers for Alzheimer’s disease
The BIO International Convention is a huge gathering each year, as around 15-18,000 representatives from across industry and around the world get together to discuss policy, partnering, and product development over the course of four days. This year’s event, to be held in Boston from June 4 – 7, should be no exception. BIO has...
12
Mar
2018
Bionest
Alzheimer’s Disease: Continued Clinical Failure and a Potential New Development Pathway
Alzheimer’s disease continues to be a costly and frustrating minefield for drug developers. Most recently, Boehringer Ingelheim halted development of the phosphodiesterase type 9 (PDE9) inhibitor BI 409306 after it failed in phase 2. Merck also ended its trial of verubecestat, the company’s beta-secretase-1 (BACE1) inhibitor, in early stage Alzheimer’s disease patients for futility, a few...
23
Jan
2018